• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients.危重症感染和创伤患者的抗生素给药:脓毒症和创伤患者的病理生理学与药代动力学/药效学关联
BMC Anesthesiol. 2011 Feb 20;11:3. doi: 10.1186/1471-2253-11-3.
2
The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery.头孢唑林在择期和半择期腹主动脉瘤开放修复手术患者中的药代动力学。
BMC Anesthesiol. 2011 Feb 22;11:5. doi: 10.1186/1471-2253-11-5.
3
Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?哌拉西林在脓毒症重症患者组织中的渗透——静脉推注与持续给药对比?
Crit Care Med. 2009 Mar;37(3):926-33. doi: 10.1097/CCM.0b013e3181968e44.
4
Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.哌拉西林他唑巴坦在接受连续性静脉-静脉血液透析滤过的危重症患者血浆和皮下组织间液中的药代动力学。
Int J Antimicrob Agents. 2014 Apr;43(4):343-8. doi: 10.1016/j.ijantimicag.2014.01.009. Epub 2014 Feb 10.
5
Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.危重症患者时间依赖性β-内酰胺类抗生素有效给药方案的协变量决定因素。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Sep;162(3):219-226. doi: 10.5507/bp.2018.011. Epub 2018 Mar 27.
6
Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients.创伤后重症患者中头孢唑林的血浆和靶部位皮下组织群体药代动力学及给药模拟
J Antimicrob Chemother. 2015 May;70(5):1495-502. doi: 10.1093/jac/dku564. Epub 2015 Jan 20.
7
SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients.肾脏替代治疗中抗生素的采样(SMARRT):一项针对危重症患者的观察性药代动力学研究。
BMC Infect Dis. 2016 Mar 1;16:103. doi: 10.1186/s12879-016-1421-6.
8
[Personalised antibiotic therapy in a surgical intensive care unit overview of current knowledge and the results of an observational kinetic study].[外科重症监护病房的个体化抗生素治疗:当前知识概述及一项观察性动力学研究结果]
Rozhl Chir. 2014 Sep;93(9):456-62.
9
A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.一项关于接受哌拉西林/他唑巴坦治疗的重症患者药代动力学/药效学目标达成情况的试点研究。
Anaesthesiol Intensive Ther. 2016;48(1):23-8. doi: 10.5603/AIT.a2015.0082. Epub 2015 Nov 20.
10
Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.哌拉西林他唑巴坦在危重症肥胖外科患者中的药代动力学分析。
Pharmacotherapy. 2014 Jan;34(1):28-35. doi: 10.1002/phar.1324. Epub 2013 Jul 17.

引用本文的文献

1
elimination of antimicrobials during ADVanced Organ Support hemodialysis.在高级器官支持血液透析过程中抗菌药物的清除
Front Pharmacol. 2024 Dec 16;15:1447511. doi: 10.3389/fphar.2024.1447511. eCollection 2024.
2
Therapeutic Drug Monitoring of Antimicrobials in Critically Ill Obese Patients.危重症肥胖患者抗菌药物的治疗药物监测
Antibiotics (Basel). 2023 Jun 24;12(7):1099. doi: 10.3390/antibiotics12071099.
3
β-Lactam Dosing in Critical Patients: A Narrative Review of Optimal Efficacy and the Prevention of Resistance and Toxicity.重症患者的β-内酰胺类药物给药:关于最佳疗效以及预防耐药性和毒性的叙述性综述
Antibiotics (Basel). 2022 Dec 18;11(12):1839. doi: 10.3390/antibiotics11121839.
4
Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.新型β-内酰胺类药物和β-内酰胺/β-内酰胺酶抑制剂在危重症成年患者中的药代动力学、药效学及给药考量:聚焦肥胖、肾脏清除率增加、肾脏替代治疗及体外膜肺氧合
J Clin Med. 2022 Nov 22;11(23):6898. doi: 10.3390/jcm11236898.
5
Optimizing Antimicrobial Drug Dosing in Critically Ill Patients.优化重症患者的抗菌药物给药方案
Microorganisms. 2021 Jun 28;9(7):1401. doi: 10.3390/microorganisms9071401.
6
Optimizing the Use of Antibiotic Agents in the Pediatric Intensive Care Unit: A Narrative Review.优化儿科重症监护病房抗生素药物的使用:叙述性综述。
Paediatr Drugs. 2021 Jan;23(1):39-53. doi: 10.1007/s40272-020-00426-y. Epub 2020 Nov 10.
7
A survey of antibiotic administration practices involving patients with sepsis in UK critical care units.英国重症监护病房脓毒症患者抗生素使用情况调查。
Int J Clin Pharm. 2020 Feb;42(1):65-71. doi: 10.1007/s11096-019-00938-9. Epub 2019 Nov 14.
8
Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.健康受试者和肾功能不全患者中头孢洛扎/他唑巴坦的群体药代动力学研究
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.01265-19. Print 2019 Oct.
9
A Population Pharmacokinetic Analysis to Study the Effect of Extracorporeal Membrane Oxygenation on Cefepime Disposition in Children.一项群体药代动力学分析研究体外膜肺氧合对儿童头孢吡肟处置的影响。
Pediatr Crit Care Med. 2019 Jan;20(1):62-70. doi: 10.1097/PCC.0000000000001786.
10
Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.哌拉西林在非肥胖、肥胖和病态肥胖重症患者中的群体药代动力学
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01276-16. Print 2017 Mar.

本文引用的文献

1
Pitfalls of using estimations of glomerular filtration rate in an intensive care population.在重症监护人群中使用肾小球滤过率估计值的陷阱。
Intern Med J. 2011 Jul;41(7):537-43. doi: 10.1111/j.1445-5994.2009.02160.x.
2
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.危重症患者β-内酰胺类药物的治疗药物监测:概念验证。
Int J Antimicrob Agents. 2010 Oct;36(4):332-9. doi: 10.1016/j.ijantimicag.2010.06.008. Epub 2010 Aug 3.
3
Augmented renal clearance: implications for antibacterial dosing in the critically ill.增强的肾功能清除:对危重症患者抗菌药物剂量的影响。
Clin Pharmacokinet. 2010;49(1):1-16. doi: 10.2165/11318140-000000000-00000.
4
Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.脓毒症且无肾功能不全的危重症患者的美罗培南给药:静脉推注与持续给药对比?蒙特卡洛模拟给药及皮下组织分布情况
J Antimicrob Chemother. 2009 Jul;64(1):142-50. doi: 10.1093/jac/dkp139. Epub 2009 Apr 27.
5
Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?哌拉西林在脓毒症重症患者组织中的渗透——静脉推注与持续给药对比?
Crit Care Med. 2009 Mar;37(3):926-33. doi: 10.1097/CCM.0b013e3181968e44.
6
Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia.反馈剂量调整对医院获得性肺炎中病原体清除的概率有显著影响。
Eur Respir J. 2009 Aug;34(2):394-400. doi: 10.1183/09031936.00149508. Epub 2009 Feb 12.
7
Antibiotic resistance--what's dosing got to do with it?抗生素耐药性——给药剂量与之有何关系?
Crit Care Med. 2008 Aug;36(8):2433-40. doi: 10.1097/CCM.0b013e318180fe62.
8
G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences.G*Power 3:一款适用于社会科学、行为科学和生物医学科学的灵活的统计功效分析程序。
Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146.
9
Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role.β-内酰胺类抗生素在严重感染中的持续输注:作用综述
Int J Antimicrob Agents. 2007 Jul;30(1):11-8. doi: 10.1016/j.ijantimicag.2007.02.002. Epub 2007 Apr 17.
10
Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria.头孢匹罗在重症患者中针对革兰氏阴性菌的群体药代动力学和药效学
Intensive Care Med. 2007 May;33(5):781-788. doi: 10.1007/s00134-007-0573-7. Epub 2007 Mar 7.

危重症感染和创伤患者的抗生素给药:脓毒症和创伤患者的病理生理学与药代动力学/药效学关联

Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients.

机构信息

Burns, Trauma and Critical Care Research Centre, The University of Queensland, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

出版信息

BMC Anesthesiol. 2011 Feb 20;11:3. doi: 10.1186/1471-2253-11-3.

DOI:10.1186/1471-2253-11-3
PMID:21333028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3050838/
Abstract

BACKGROUND

Critical illness, mediated by trauma or sepsis, can lead to physiological changes that alter the pharmacokinetics of antibiotics and may result in sub-therapeutic concentrations at the sites of infection. The first aim of this project is to identify the clinical characteristics of critically ill patients with significant trauma that have been recently admitted to ICU that may predict the dosing requirements for the antibiotic, cefazolin. The second aim of this is to identify the clinical characteristics of critically ill patients with sepsis that may predict the dosing requirements for the combination antibiotic, piperacillin-tazobactam.

METHODS/DESIGN: This is an observational pharmacokinetic study of patients with trauma (cefazolin) or with sepsis (piperacillin-tazobactam). Participants will have samples from blood and urine, collected at different intervals. Patients will also have a microdialysis catheter inserted into subcutaneous tissue to measure interstitial fluid penetration of the antibiotic. Participants will be administered sinistrin, indocyanine green and sodium bromide as well as have cardiac output monitoring performed and tetrapolar bioimpedance to determine physiological changes resulting from pathology. Analysis of samples will be performed using validated liquid chromatography tandem mass-spectrometry. Pharmacokinetic analysis will be performed using non-linear mixed effects modeling to determine individual and population pharmacokinetic parameters of antibiotics.

DISCUSSION

The study will describe cefazolin and piperacillin-tazobactam concentrations in plasma and the interstitial fluid of tissues in trauma and sepsis patients respectively. The results of this study will guide clinicians to effectively dose these antibiotics in order to maximize the concentration of antibiotics in the interstitial fluid of tissues.

摘要

背景

创伤或脓毒症引起的危重病可导致改变抗生素药代动力学的生理变化,并可能导致感染部位的治疗浓度不足。本项目的第一个目的是确定最近入住 ICU 的严重创伤患者的临床特征,这些特征可能预测抗生素头孢唑林的剂量需求。本项目的第二个目的是确定患有脓毒症的危重病患者的临床特征,这些特征可能预测联合抗生素哌拉西林-他唑巴坦的剂量需求。

方法/设计:这是一项关于创伤(头孢唑林)或脓毒症(哌拉西林-他唑巴坦)患者的观察性药代动力学研究。参与者将在不同时间间隔采集血液和尿液样本。患者还将在皮下组织中插入微透析导管,以测量抗生素的间质液渗透。参与者将接受辛替斯汀、吲哚菁绿和溴化钠给药,并进行心输出量监测和四极生物电阻抗测量,以确定病理引起的生理变化。使用经过验证的液相色谱串联质谱法分析样品。使用非线性混合效应模型进行药代动力学分析,以确定抗生素的个体和群体药代动力学参数。

讨论

该研究将描述头孢唑林和哌拉西林-他唑巴坦在创伤和脓毒症患者的血浆和组织间质液中的浓度。本研究的结果将指导临床医生有效地给予这些抗生素,以最大限度地提高组织间质液中抗生素的浓度。